HHS Public Access Author manuscript Author Manuscript
Clin Cardiol. Author manuscript; available in PMC 2017 September 13. Published in final edited form as: Clin Cardiol. 2017 June ; 40(6): 347–355. doi:10.1002/clc.22686.
Optimal Secondary Prevention Medication Use in Acute Myocardial Infarction Patients with Non-Obstructive Coronary Artery Disease is Modified by Management Strategy: Insights from the TRIUMPH Registry
Author Manuscript
Reynaria Pitts, MD1, Stacie L. Daugherty, MD, MSPH1,5, Fengming Tang2, Philip Jones2, P. Michael Ho, MD, PhD1,3, Thomas T. Tsai, MD MSc4,5, John Spertus, MD MPH2, and Thomas M. Maddox, MD MSc1,3 1University
of Colorado School of Medicine, Aurora, CO
2Saint
Luke’s/Mid America Heart Institute and the University of Missouri - Kansas City, Kansas City, KS 3VA
Eastern Colorado Health Care System, Denver, CO
4Institute
for Health Research, Kaiser Permanente, Denver, CO
5Colorado
Cardiovascular Outcomes Research (CCOR) Consortium, Denver, CO
Abstract Author Manuscript
Background—Patients with acute myocardial infarction (AMI) and non-obstructive coronary artery disease (nonobCAD) may be perceived to be at lower risk for cardiac events, relative to those with obstructive CAD (obCAD), and thus less likely to receive optimal preventive medications in the year following AMI. We aimed to determine if AMI patients with nonobCAD, compared to obCAD, received lower rates of prevention medications in the year following AMI.
Author Manuscript
Methods and Results—We compared optimal prevention medication use at hospital discharge, 1, 6, and 12 months after hospitalization. Optimal medication use was defined as the receipt of all prevention medications for which that patient was eligible (e.g. aspirin, clopidogrel, statins, betablockers and ACEI/ARBs). We used multivariable logistic regression analyses to determine the association between nonobCAD to medication use and adjusted for potential confounders. 3630 AMI patients were studied, of which 200 (5.2%) had nonobCAD. Fewer nonobCAD patients received optimal medication use compared to obCAD patients at discharge (31% v. 65%, p
Clin Cardiol. Author manuscript; available in PMC 2017 September 13. Published in final edited form as: Clin Cardiol. 2017 June ; 40(6): 347–355. doi:10.1002/clc.22686.
Optimal Secondary Prevention Medication Use in Acute Myocardial Infarction Patients with Non-Obstructive Coronary Artery Disease is Modified by Management Strategy: Insights from the TRIUMPH Registry
Author Manuscript
Reynaria Pitts, MD1, Stacie L. Daugherty, MD, MSPH1,5, Fengming Tang2, Philip Jones2, P. Michael Ho, MD, PhD1,3, Thomas T. Tsai, MD MSc4,5, John Spertus, MD MPH2, and Thomas M. Maddox, MD MSc1,3 1University
of Colorado School of Medicine, Aurora, CO
2Saint
Luke’s/Mid America Heart Institute and the University of Missouri - Kansas City, Kansas City, KS 3VA
Eastern Colorado Health Care System, Denver, CO
4Institute
for Health Research, Kaiser Permanente, Denver, CO
5Colorado
Cardiovascular Outcomes Research (CCOR) Consortium, Denver, CO
Abstract Author Manuscript
Background—Patients with acute myocardial infarction (AMI) and non-obstructive coronary artery disease (nonobCAD) may be perceived to be at lower risk for cardiac events, relative to those with obstructive CAD (obCAD), and thus less likely to receive optimal preventive medications in the year following AMI. We aimed to determine if AMI patients with nonobCAD, compared to obCAD, received lower rates of prevention medications in the year following AMI.
Author Manuscript
Methods and Results—We compared optimal prevention medication use at hospital discharge, 1, 6, and 12 months after hospitalization. Optimal medication use was defined as the receipt of all prevention medications for which that patient was eligible (e.g. aspirin, clopidogrel, statins, betablockers and ACEI/ARBs). We used multivariable logistic regression analyses to determine the association between nonobCAD to medication use and adjusted for potential confounders. 3630 AMI patients were studied, of which 200 (5.2%) had nonobCAD. Fewer nonobCAD patients received optimal medication use compared to obCAD patients at discharge (31% v. 65%, p
